IGC Pharma has expanded its Phase 2 CALMA clinical trial for IGC-AD1, a treatment for agitation in Alzheimer's dementia, to a new site at Tekton Research in Yukon, Oklahoma. The expansion, led by board-certified neurologist Dr. David McCoy as principal investigator, aims to diversify the trial population and address regional healthcare disparities in the Oklahoma City metropolitan area. Tekton Research brings extensive experience in conducting clinical trials across various therapeutic areas including Alzheimer's disease, migraine, and vaccines. The site is now accepting patient enrollments, with interested participants able to contact Tekton Research directly through their Yukon facility.
IGC Pharma ha ampliato il suo studio clinico di Fase 2 CALMA per IGC-AD1, un trattamento per l'agitazione nella demenza di Alzheimer, includendo un nuovo centro presso Tekton Research a Yukon, Oklahoma. L'espansione, guidata dal neurologo certificato Dr. David McCoy come investigatore principale, punta a diversificare la popolazione dello studio e a ridurre le disparit脿 sanitarie nella zona metropolitana di Oklahoma City. Tekton Research vanta una vasta esperienza nella conduzione di studi clinici in diverse aree terapeutiche, tra cui la malattia di Alzheimer, l'emicrania e i vaccini. Il centro 猫 ora aperto alle iscrizioni dei pazienti, che possono contattare direttamente Tekton Research presso la struttura di Yukon.
IGC Pharma ha ampliado su ensayo cl铆nico de Fase 2 CALMA para IGC-AD1, un tratamiento para la agitaci贸n en la demencia de Alzheimer, incorporando un nuevo sitio en Tekton Research en Yukon, Oklahoma. La expansi贸n, liderada por el neur贸logo certificado Dr. David McCoy como investigador principal, busca diversificar la poblaci贸n del ensayo y abordar las disparidades en la atenci贸n m茅dica en el 谩rea metropolitana de Oklahoma City. Tekton Research cuenta con amplia experiencia en la realizaci贸n de ensayos cl铆nicos en diversas 谩reas terap茅uticas, incluyendo la enfermedad de Alzheimer, migra帽as y vacunas. El sitio ya est谩 aceptando inscripciones de pacientes, quienes pueden contactar directamente a Tekton Research en su instalaci贸n de Yukon.
IGC Pharma a 茅tendu son essai clinique de phase 2 CALMA pour IGC-AD1, un traitement contre l鈥檃gitation dans la d茅mence d鈥橝lzheimer, 脿 un nouveau site chez Tekton Research 脿 Yukon, Oklahoma. Cette expansion, dirig茅e par le neurologue certifi茅 Dr. David McCoy en tant qu鈥檌nvestigateur principal, vise 脿 diversifier la population de l鈥檈ssai et 脿 r茅duire les disparit茅s en mati猫re de soins de sant茅 dans la r茅gion m茅tropolitaine d鈥橭klahoma City. Tekton Research poss猫de une vaste exp茅rience dans la conduite d鈥檈ssais cliniques dans divers domaines th茅rapeutiques, notamment la maladie d鈥橝lzheimer, la migraine et les vaccins. Le site accepte d茅sormais les inscriptions des patients, qui peuvent contacter directement Tekton Research via leur 茅tablissement de Yukon.
IGC Pharma hat seine Phase-2-Studie CALMA f眉r IGC-AD1, eine Behandlung gegen Unruhe bei Alzheimer-Demenz, auf einen neuen Standort bei Tekton Research in Yukon, Oklahoma, ausgeweitet. Die Erweiterung, geleitet vom zertifizierten Neurologen Dr. David McCoy als Hauptpr眉fer, zielt darauf ab, die Studienpopulation zu diversifizieren und regionale Gesundheitsunterschiede im Gro脽raum Oklahoma City zu adressieren. Tekton Research verf眉gt 眉ber umfangreiche Erfahrung in der Durchf眉hrung klinischer Studien in verschiedenen Therapiegebieten, darunter Alzheimer, Migr盲ne und Impfstoffe. Der Standort nimmt nun Patientenanmeldungen entgegen, interessierte Teilnehmer k枚nnen direkt Kontakt mit Tekton Research in der Einrichtung in Yukon aufnehmen.
Positive
None.
Negative
None.
POTOMAC, MD / / June 23, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the addition of a new clinical trial site at Tekton Research in Yukon, Oklahoma, for its Phase 2 CALMA study evaluating IGC-AD1 for agitation in Alzheimer's dementia. This expansion into the Oklahoma City metropolitan area underscores IGC's commitment to diversifying its trial population and addressing regional healthcare disparities.
Tekton Research has extensive experience conducting clinical trials in therapeutic areas such as Alzheimer's disease, migraine, vaccines, and others. Dr. David McCoy, a board-certified neurologist in Canadian County and a native Oklahoman, will serve as the principal investigator at the Yukon site. Dr. McCoy plays a key role in his community by providing accessible healthcare and maintaining strong relationships with his patients.
"We are excited to collaborate with Dr. McCoy and Tekton Research to bring the CALMA trial to the Yukon community," said Ram Mukunda, CEO of IGC Pharma. "Expanding our trial to Oklahoma allows us to reach a broader and more diverse patient population, which is essential for the development of effective and inclusive treatments for Alzheimer's-related agitation."
Patients and caregivers interested in participating in the CALMA trial at the Yukon site can contact Tekton Research at 1804 Commons Circle, Suite B, Yukon, OK 73099, call (405) 594-7712, or email [email protected]. For more information, visit .
About IGC-AD1 and the CALMA Trial
IGC-AD1 is IGC Pharma's investigational cannabinoid-based therapy currently in a Phase 2 multicenter, double-blind, randomized, placebo-controlled study (CALMA) evaluating its safety and efficacy for treating agitation in Alzheimer's dementia. Agitation affects up to 76% of Alzheimer's patients, often leading to increased hospitalization and caregiver burden. IGC-AD1 acts as a partial CB1 receptor agonist with anti-neuroinflammatory properties, targeting key pathways involved in neuroinflammation, oxidative stress, and neurotransmitter imbalances.
For more information on the CALMA trial, visit: .
About IGC Pharma (dba IGC):
(NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial () for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize , and enhance patient targeting. With 30 patent filings and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
About Tekton
Founded in 2006, Tekton Research is a multi-state clinical research site network conducting Phase 1-4 trials in CNS, cardiometabolic, general medicine and infectious disease. Led by seasoned professionals and nationally recognized KOLs, Tekton delivers scientific rigor and operational excellence across trials of any size. The company partners with sponsors, CROs, and biopharma to accelerate the development of new therapies while maintaining a strong commitment to patient-centered care.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Qs filed with the SEC on August 7, 2024, November 12, 2024, and February 14, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian/Walter Frank IMS Investor Relations [email protected] (203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original on ACCESS Newswire
FAQ
What is the purpose of IGC Pharma's CALMA trial expansion to Oklahoma?
The expansion aims to diversify the trial population and address regional healthcare disparities in evaluating IGC-AD1 for agitation in Alzheimer's dementia patients.
Who is leading IGC's CALMA trial at the new Yukon, Oklahoma site?
Dr. David McCoy, a board-certified neurologist and native Oklahoman, will serve as the principal investigator at the Tekton Research site in Yukon.
How can patients participate in IGC Pharma's CALMA trial in Yukon, Oklahoma?
Interested patients can contact Tekton Research at 1804 Commons Circle, Suite B, Yukon, OK 73099, call (405) 594-7712, or email [email protected].
What experience does Tekton Research have in clinical trials?
Tekton Research has extensive experience conducting clinical trials in therapeutic areas including Alzheimer's disease, migraine, and vaccines.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
